146 related articles for article (PubMed ID: 36399360)
1. Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs.
Liu J; Zhang Y; Kaplan CM
Health Econ; 2023 Mar; 32(3):639-653. PubMed ID: 36399360
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
3. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
4. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
Bonakdar Tehrani A; Cunningham PJ
Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
[TBL] [Abstract][Full Text] [Related]
5. Differential Effects by Mental Health Status of Filling the Medicare Part D Coverage Gap.
Liu J; Zhang Y; Kaplan CM
Med Care; 2022 Feb; 60(2):133-139. PubMed ID: 35030562
[TBL] [Abstract][Full Text] [Related]
6. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
Mishuk AU; Fasina I; Qian J
Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
[TBL] [Abstract][Full Text] [Related]
7. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
Socal MP; Bai G; Anderson GF
JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
11. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
12. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
13. The Medicare Part D Coverage Gap, Prescription Use, and Expenditures.
Unuigbe A
Med Care Res Rev; 2020 Oct; 77(5):442-450. PubMed ID: 30336732
[TBL] [Abstract][Full Text] [Related]
14. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
15. The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure.
Baik SH; Rollman BL; Reynolds CF; Lave JR; Smith KJ; Zhang Y
J Ment Health Policy Econ; 2012 Sep; 15(3):105-18. PubMed ID: 23001279
[TBL] [Abstract][Full Text] [Related]
16. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures.
Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM
J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313
[TBL] [Abstract][Full Text] [Related]
17. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
18. Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure.
Gokhale M; Dusetzina SB; Pate V; Chun DS; Buse JB; Stürmer T; Gower EW
Diabetes Care; 2020 Sep; 43(9):2121-2127. PubMed ID: 32641378
[TBL] [Abstract][Full Text] [Related]
19. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
Lakdawalla D; Li M
JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
[TBL] [Abstract][Full Text] [Related]
20. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
Song H; Adamson A; Mostaghimi A
JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
